依达拉奉联合低分子肝素治疗进展性卒中的疗效观察

Clinical observation of treatment of progressive stroke with edaravone and low molecular weight heparin

目的观察依达拉奉联合低分子肝素治疗进展性卒中的疗效。方法对140例急性进展性卒中的患者随机分为依达拉奉联合低分子肝素治疗组(n=70)和低分子肝素对照组(n=70)。治疗组在常规治疗的基础上加用依达拉奉30 mg加入生理盐水100 ml中静滴,2次/d,连用14 d,同时给予低分子肝素5000 u腹部皮下注射2次/d,连用7 d。对照组在常规治疗的基础上只加用低分子肝素。于治疗前及治疗第14 d分别进行临床疗效及神经功能缺损评分。结果两组于治疗前后神经功能缺损评分、临床疗效均有改善,治疗组总有效率90.00%,对照组总有效率75.71%,治疗组改善更明显,与对照组相比有显著性差异(P<0.01)。结论依达拉奉联合低分子肝素治疗进展性卒中疗效确切,不良反应少,值得推广。

Objective To observe the clinical effect of treatment of progressive stroke with edaravone and low molecular weight heparin. Methods 140 patients with progressive stroke were randomly divided into two groups, treatment group （70 cases） treated with edaravone and low molecular weight heparin and control group （70 cases） treated with low molecular weight heparin only. With same normal basic treatments on the 2 groups, the treatment group was intravenous drop-injected with 30mg edaravone twice a day for 14 days. Meanwhile, they were injected with 5000iu low molecular weight heparin twice a day for 7days. The control group was treated with low molecular weight heparin only. The neural function deficits and the clinical curative effects before the treatment and on the 14th day after the treatment were ob- served. Results The neural function deficits evaluation indicates that there were improvements of the two groups after the treatment, especially of the treatment group. There was significant difference on the total effective rates （P〈0.01） between the two groups. Conclusion It is effective and safe of edaravone and low molecular weight heparin on the prevention and treatment of stroke in progression.